Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 949-955

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study

By Goldstein Barry J.   Weissman Peter N.   Wooddell Margaret J.   Waterhouse Brian R.   Cobitz Alexander R.  

Current Medical Research and Opinion, Vol. 22, Iss. 9, 2006-09 ,pp. : 1715-1723

Informa Healthcare

Access to resources Recommend Favorite

Optimizing treatment of diabetes and cardiovascular disease with combined α,β-blockade

By Bell David S. H.  

Current Medical Research and Opinion, Vol. 21, Iss. 8, 2005-08 ,pp. : 1191-1200

Informa Healthcare

Access to resources Recommend Favorite

Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus

By Derosa Giuseppe   Salvadeo Sibilla AT   Cicero Arrigo FG  

Therapy, Vol. 3, Iss. 5, 2006-09 ,pp. : 559-569

Future Medicine

Access to resources Recommend Favorite

Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone

By  

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 234-244

Bentham Science Publishers

Access to resources Recommend Favorite